| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
| US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
| US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
|
US9610265 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
|
US9987238 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
| US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(7 years from now) | |
|
US9399012 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(8 years from now) | |
Ofirmev is owned by Mallinckrodt Hosp.
Ofirmev contains Acetaminophen.
Ofirmev has a total of 7 drug patents out of which 0 drug patents have expired.
Ofirmev was authorised for market use on 02 November, 2010.
Ofirmev is available in solution;intravenous dosage forms.
Ofirmev can be used as modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics, modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics, modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain, modified dosing regimen for the reduction of fever; modified dosing regimen for the management of mild to moderate pain or management of moderate to severe pain as an adjunct to opioid analgesics.
The generics of Ofirmev are possible to be released after 11 March, 2032.
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate t...
Dosage: SOLUTION;INTRAVENOUS
OFIRMEV family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic